Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 05, 2015 1:00 PM ET

Biotechnology

Company Overview of CareDx, Inc

Company Overview

CareDx, Inc, a commercial stage company, develops, markets, and delivers diagnostic surveillance solutions for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. Its commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a blood-based test used to monitor heart transplant recipients for acute cellular rejection. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners in the United States, Canada, and Europe. The company was formerly known as XDx...

3260 Bayshore Boulevard

Brisbane, CA 94005

United States

Founded in 1998

68 Employees

Phone:

415-287-2300

Fax:

415-287-2450

Key Executives for CareDx, Inc

Chief Executive Officer, President and Director
Age: 47
Total Annual Compensation: $547.6K
Chief Medical Officer and Executive Vice President
Age: 65
Total Annual Compensation: $524.5K
Chief Compliance Officer and Chief Business Officer
Age: 44
Total Annual Compensation: $445.5K
Compensation as of Fiscal Year 2014.

CareDx, Inc Key Developments

CareDx, Inc. Announces First Patients Enrolled in Largest-Ever Multicenter Kidney Transplant Study Using Cell-Free DNA Technology

CareDx Inc. announced that the Cleveland Clinic has enrolled the first patients into a multicenter observational study designed to demonstrate the clinical performance characteristics of circulating cell-free DNA (cfDNA) in detecting clinical and sub-clinical rejection in kidney allograft recipients. The study is also designed to demonstrate the correlation of circulating cfDNA to renal function, both serum creatinine and estimated glomerular filtration rate. The Circulating Donor-Derived Cell-Free DNA in blood for diagnosing Acute Rejection in Kidney Transplant Recipients (DART) study is a prospective, multicenter, observational study of de-novo kidney transplant subjects where blood specimens will be drawn periodically after transplant and also after treatment for acute rejection. The first phase of the DART study is expected to enroll 200 patients in at least ten centers over a minimum of 18 months. A second phase of the DART study, to establish clinical utility, is expected to commence after initial results are obtained from the first phase.

CareDx, Inc - Shareholder/Analyst Call

CareDx, Inc - Shareholder/Analyst Call

CareDx, Inc Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for the Full Year of 2015

CareDx Inc. announced financial results for the fourth quarter and year ended December 31, 2014. Revenue for the three months ended December 31, 2014 increased 36% to $8.0 million, from $5.9 million in the same period in 2013. Of the $8.0 million in revenue, $1.1 million was associated with the payments from LabCorp. For the fourth quarter of 2014, net loss was $5,000 and basic and diluted net income per share was $0.00, compared to $562,000 or $0.56 per diluted share a year ago. Income from operations was $429,000 compared to $509,000 a year ago. Loss before income taxes was $5,000 compared to $562,000 a year ago. For the full year 2014, revenues were $27.3 million versus $22.1 million in 2013, an increase of 24%. Net income for fiscal year 2014 was $781,000 compared to a net loss of $3.5 million for fiscal year 2013. Basic and diluted income per share were $0.13 and $0.10 for fiscal year 2014 compared to a $3.50 loss for both basic and diluted earnings per share for fiscal year 2013. Income from operations was $1,250,000 compared to loss of $857,000 a year ago. Loss before income taxes was $719,000 compared to $3,542,000 a year ago. The company is providing revenue guidance for the full year of 2015. Revenue is expected to be in the range of $28 million to $30 million.

Similar Private Companies By Industry

Company Name Region
Immune Cell Therapy, Inc. United States
Agtech Products, Inc. United States
MiPod Nuclear Inc. United States
Cambrex Bio Science Walkersville, Inc. United States
Modular Genetics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 30, 2015
--
Merger/Acquisition
May 21, 2014
ImmuMetrix, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CareDx, Inc, please visit www.caredx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.